Serum Dipeptidyl Peptidase 4: A Predictor of Disease Activity and Prognosis in Inflammatory Bowel Disease
| Autor: | Cátia Rocha, Pedro Pinto-Lopes, Fernando Magro, Paula Lago, Joana Afonso, Rui Pinto-Lopes, Cláudia Camila Dias, Guilherme Macedo, Raquel Gonçalves, Helena Sousa |
|---|---|
| Přispěvatelé: | Repositório da Universidade de Lisboa |
| Rok vydání: | 2020 |
| Předmět: |
Adult
Male 0301 basic medicine medicine.medical_specialty Treatment response Dipeptidyl peptidase 4 Severity of Illness Index Inflammatory bowel disease Gastroenterology Disease activity Feces 03 medical and health sciences 0302 clinical medicine Crohn Disease Predictive Value of Tests Internal medicine medicine Humans Immunology and Allergy Prospective Studies Dipeptidyl peptidase-4 Gastroenterology & Hepatology business.industry Remission Induction Prognosis medicine.disease Ulcerative colitis C-Reactive Protein 030104 developmental biology Cohort Biomarker (medicine) Colitis Ulcerative Female 030211 gastroenterology & hepatology Drug Monitoring Calprotectin business Leukocyte L1 Antigen Complex Biomarkers |
| Zdroj: | Repositório Científico de Acesso Aberto de Portugal Repositório Científico de Acesso Aberto de Portugal (RCAAP) instacron:RCAAP |
| ISSN: | 1536-4844 1078-0998 |
| Popis: | © 2020 Crohn’s & Colitis Foundation. Published by Oxford University Press. All rights reserved. This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model. A correction has been published: Inflammatory Bowel Diseases, Volume 26, Issue 6, June 2020, Page e56, https://doi.org/10.1093/ibd/izaa058 Background: Serum dipeptidyl peptidase 4 (DPP-4) has drawn particular interest as a biomarker in inflammatory bowel disease (IBD), as this protease inactivates several peptides that participate in the inflammatory cascade. Methods: Two prospectively recruited cohorts consisting of 195 patients (101 had Crohn’s disease [CD] and 94 had ulcerative colitis [UC]) were evaluated using clinical indexes and followed up to assess for treatment escalation. Sixty-eight patients underwent endoscopic evaluation at baseline. In the second cohort of 46 biologically treated patients, treatment response was assessed. Serum DPP-4, C-reactive protein (CRP), and fecal calprotectin levels were quantified at baseline and during follow-up. Results: Median DPP-4 levels were significantly lower in active IBD patients when compared with remitters (CD: 1043 [831–1412] vs 1589 [1255–1956] ng/mL; P < 0.001; UC: 1317 [1058–1718] vs 1798 [1329–2305] ng/mL; P = 0.001) and healthy controls (2175 [1875–3371] ng/mL). In fact, DPP-4 was able to distinguish clinical and endoscopic activity from remission, with areas under the curve (AUC) of 0.81/0.93 (CD) and 0.71/0.79 (UC), along with the need for treatment escalation, with comparable AUCs of 0.79 (CD) and 0.77 (UC). Furthermore, DPP-4 levels were higher in responders to treatment and more pronounced among UC (1467 [1301–1641] vs 1211 [1011–1448] ng/mL; P < 0.001) than CD patients (1385 [1185–1592] vs 1134 [975–1469] ng/mL; P = 0.015). Conclusions: Our results suggest that serum DPP-4 can be used as a noninvasive biomarker of IBD activity and biological treatment response and a predictor of treatment escalation, particularly when combined with other biomarkers. This work was supported by the Portuguese IBD Study Group (Grupo de Estudo da Doença Inflamatória Intestinal [GEDII]) and a research grant from Janssen-Cilag Pharmaceuticals. C.R. would like to acknowledge funding from “Fundação para a Ciência e Tecnologia (FCT),” Portugal, under grant number PDE/BDE/114583/2016 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|